Steven R Horbal, Michael E Hall, Paul C Dinh, Abbas Smiley, Solomon K Musani, Jiankang Liu, Herman A Taylor, Ervin R Fox, Aurelian Bidulescu
{"title":"Associations of adiponectin and leptin with brain natriuretic peptide in African Americans: the Jackson Heart Study.","authors":"Steven R Horbal, Michael E Hall, Paul C Dinh, Abbas Smiley, Solomon K Musani, Jiankang Liu, Herman A Taylor, Ervin R Fox, Aurelian Bidulescu","doi":"10.1097/XCE.0000000000000198","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000198","url":null,"abstract":"<p><p>Brain natriuretic peptide (BNP) is elevated in decompensated systolic and diastolic heart failure. The plasma levels of adipokines, such as adiponectin and leptin, may provide evidence for mechanistic differences in BNP concentrations. African-American-specific associations are limited in the literature. The objective of this study was to evaluate the associations of adiponectin and leptin with BNP among African Americans.</p><p><strong>Methods: </strong>Linear and logistic regressions were used to test the associations between adiponectin, leptin, and plasma BNP in 3738 participants of the Jackson Heart Study (JHS), a single-site prospective cohort study of African Americans in Jackson, Mississippi.</p><p><strong>Results: </strong>A direct relationship of adiponectin was observed in multiple multivariate-adjusted linear models: in men (<i>β</i> = 0.41-0.47), and in women (<i>β</i> = 0.32-0.38). Those in the highest quartile of adiponectin expression were twice as likely to have elevated BNP levels after adjustment [odds ratio 2.66 (95% confidence interval, 1.66-4.34)]. An inverse relationship of leptin with BNP was observed (<i>β</i> = -0.15) but attenuated after adjustment for aldosterone, renin, and adiponectin.</p><p><strong>Conclusions: </strong>Different linear associations of adiponectin and leptin with BNP were observed. Odds of elevated adiponectin were observed with elevated BNP in multivariate-adjusted models. This paradoxical relationship of adiponectin and plasma BNP is possibly explained through adiponectin resistance.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 2","pages":"49-55"},"PeriodicalIF":2.3,"publicationDate":"2020-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000198","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38044012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ertan Yetkin, Selcuk Ozturk, Bilal Cuglan, Hasan Turhan
{"title":"Clinical presentation of paroxysmal supraventricular tachycardia: evaluation of usual and unusual symptoms.","authors":"Ertan Yetkin, Selcuk Ozturk, Bilal Cuglan, Hasan Turhan","doi":"10.1097/XCE.0000000000000208","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000208","url":null,"abstract":"<p><strong>Objective: </strong>Clinical presentation of paroxysmal supraventricular tachycardia may vary from asymptomatic occurrence or mild perception of palpitation to severe chest pain or syncope. This variation is the most challenging issue in the diagnostic evaluation of rhythm disturbances and paroxysmal supraventricular tachycardia as well. This study sought to evaluate the symptoms during the tachycardia attack or index event in patients who underwent electrophysiological study and ablation procedure.</p><p><strong>Methods: </strong>This retrospective study included 100 consecutive patients who underwent electrophysiological study and ablation procedures due to supraventricular tachycardia. Structural heart disease, moderate/severe valvular pathology, systemic pathologies, such as connective tissue disease and chronic obstructive lung disease, history of pacemaker implantation was defined as exclusion criteria. In addition, medically managed patients and patients with unsuccessful ablation were not included in the study.</p><p><strong>Results: </strong>Palpitation was the most frequently observed symptom in 84% of patients, followed by chest pain in 47%, dyspnea in 38%, syncope 26%, lightheadedness in 19%, and sweating in 18% of the patients. The most common symptoms after tachycardia event were fatigue and lightheadedness with frequencies of 56% and 55%, respectively. Forty-five percent of the patients reported more than one, unusually frequent urination within the following 1-3 hours after the index event.</p><p><strong>Conclusions: </strong>Paroxysmal supraventricular tachycardia might manifest itself as gastrointestinal, neurological, psychosomatic symptoms, and unusual complaints in association with or without main symptoms, including palpitation, chest pain, syncope, and dyspnea. Symptoms after tachycardia or index event should be questioned systematically.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 4","pages":"153-158"},"PeriodicalIF":2.3,"publicationDate":"2020-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673777/pdf/xce-9-153.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38641603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Amber R Cordola Hsu, Susan L Ames, Bin Xie, Darleen V Peterson, Lorena Garcia, Scott B Going, Nathan D Wong, Hoda Anton-Culver
{"title":"Sociodemographic and metabolic risk characteristics associated with metabolic weight categories in the Women's Health Initiative.","authors":"Amber R Cordola Hsu, Susan L Ames, Bin Xie, Darleen V Peterson, Lorena Garcia, Scott B Going, Nathan D Wong, Hoda Anton-Culver","doi":"10.1097/XCE.0000000000000194","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000194","url":null,"abstract":"<p><p>To identify sociodemographic and metabolic correlates of weight categories in postmenopausal women.</p><p><strong>Methods: </strong>The Women's Health Initiative enrolled 161 808 postmenopausal women ages 50-79. We included those free of cardiovascular disease (CVD) and with CVD risk factors and biomarkers (<i>n</i> = 19 412). Normal weight was defined as a BMI ≥18.5 and <25 kg/m<sup>2</sup> and waist circumference <88 cm and overweight/obesity as a BMI ≥25 kg/m<sup>2</sup> or waist circumference ≥88 cm. Metabolically healthy was based on <2 and metabolically unhealthy ≥2 traits: triglycerides ≥150 mg/dl, systolic blood pressure (BP) ≥130 mmHg or diastolic BP ≥85 mmHg or antihypertensives or diuretics, fasting glucose ≥100 mg/dl or diabetes medication, and high-density lipoprotein cholesterol <50 mg/dl. Polytomous multinomial logistic regression with generalized link logit function provided the odds of metabolically healthy normal weight (MHNW), metabolically unhealthy normal weight (MUHNW), metabolically healthy overweight/obese (MHO), and metabolically unhealthy overweight/obese (MUHO) according to demographic and risk factor measures.</p><p><strong>Results: </strong>Among the 19 412 postmenopausal women, 2369 (12.2%) participants had prevalent diabetes. Advanced age was associated with an increased odds of MUHNW as compared with the MHNW after adjusting for covariates [odds ratio (OR) 1.04, <i>P</i> < 0.0001]. Black/African American ethnicity was associated with a decreased odds of MUHNW (OR 0.64, <i>P</i> < 0.0001) and MUHO (OR 0.77, <i>P</i> = 0.0004), while an increased odds for MHO (OR 1.50, <i>P</i> < 0.0001) as compared with White MHNW.</p><p><strong>Conclusions: </strong>Advanced age and ethnicity are important indicators of metabolic weight categories among postmenopausal women.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 2","pages":"42-48"},"PeriodicalIF":2.3,"publicationDate":"2020-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000194","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38044011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ertan Yetkin, Bilal Cuglan, Hasan Turhan, Selcuk Ozturk
{"title":"A novel strategy to reduce the readmission rates in congestive heart failure: intermittent empirical intravenous diuretics.","authors":"Ertan Yetkin, Bilal Cuglan, Hasan Turhan, Selcuk Ozturk","doi":"10.1097/XCE.0000000000000200","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000200","url":null,"abstract":"<p><p>Improvements in the medical management of heart failure have changed the course of the disease. However, mortality rates, hospitalization rates, and treatment costs are not at desired levels. Diuretics have been widely used in the treatment of congestion in heart failure patients. The following case reports represent a special patient group treated and followed by cardiology clinic. Treatment approach of each case report has been tailored on an individual basis depending on the clinical course and hospitalization rates of patients. Authors have highlighted and discussed the common aspects and future perspectives of their cases in which post-discharge intermittent empirical intravenous diuretic administration dramatically improved the clinical status and readmission number due to decompensated congestive heart failure. This is a relatively new and promising approach, which has been thought to cease the recycle of diuretic resistance and silent increase of fluid congestion in patients with congestive heart failure and frequent hospitalization.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 2","pages":"60-63"},"PeriodicalIF":2.3,"publicationDate":"2020-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000200","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38043445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Omar Sheikh, Mouhamed Nashawi, Ayman Battisha, Robert Chilton
{"title":"A focused review of cardiovascular guideline related recommendations for the primary care physician in the USA.","authors":"Omar Sheikh, Mouhamed Nashawi, Ayman Battisha, Robert Chilton","doi":"10.1097/XCE.0000000000000192","DOIUrl":"10.1097/XCE.0000000000000192","url":null,"abstract":"<p><p>Primary care physicians in the USA serve the critical role of first contact for undiagnosed or mismanaged pathologies as well as providers of continuous care in multiple communities. Their scope of practice is broad from medication reconciliation to coordinating specialty care and even performing office procedures. Primary care physicians in the USA commonly encounter patients with diabetes and associated comorbidities related to prolonged insulin resistance. Mainly these include heart failure exacerbation or major adverse cardiovascular events. The demanding roles primary care physicians serve may render these providers encumbered to navigate through long, verbose and dynamic guidelines related to managing diabetes and cardiac diabetology sequelae. Our aim is to compose current, prominent evidence-based points from American medical societies such as the American College of Cardiology/American Heart Association and the American Diabetes Association central to lifestyle modifications, antiplatelet therapy, anti-hyperglycemic and SGLT2-inhibitor utilization, hypertension, dyslipidemia, and heart failure screening in a way that is both succinct and valuable to primary care physicians.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 2","pages":"36-41"},"PeriodicalIF":2.3,"publicationDate":"2020-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228774/pdf/xce-9-36.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38044010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mouhamed Nashawi, Omar Sheikh, Mahnoor Mir, Tri Te, Robert Chilton
{"title":"The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model.","authors":"Mouhamed Nashawi, Omar Sheikh, Mahnoor Mir, Tri Te, Robert Chilton","doi":"10.1097/XCE.0000000000000204","DOIUrl":"10.1097/XCE.0000000000000204","url":null,"abstract":"<p><p>PCSK9, like other novel non-statin drugs were primarily developed to help patients achieve low-density lipoprotein cholesterol targets, especially in patients with dyslipidemia not achieving lipid goals with statins due to poor tolerance or inadequate response. PCSK9 inhibitors, in addition to modulating lipid metabolism, improve mortality outcomes in cardiovascular disease. These benefits are markedly pronounced in patients with type 2 diabetes mellitus. However, these benefits do not come without associated risk. Multiple trials, studies, and case reports have attempted to explain observed outcomes with PCSK9 expression and administration of PCSK9 inhibitors from multiple perspectives, such as their effects on insulin sensitivity and glucose tolerance, changes in renal physiology, thyroid physiology, vascular tone, intestinal regulation of lipids, and improved cardiovascular function. These agents represent an opportunity for physicians to exercise prudence by using appropriate clinical judgement when managing comorbidities in the hyperglycemic patient, a concept that extends to other novel non-statin drugs.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 4","pages":"143-152"},"PeriodicalIF":1.3,"publicationDate":"2020-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673769/pdf/xce-9-143.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38641602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antoine Fakhry AbdelMassih, David Ramzy, Lauren Nathan, Silvia Aziz, Mirette Ashraf, Nourhan Hatem Youssef, Nouran Hafez, Rana Saeed, Hala Agha
{"title":"Possible molecular and paracrine involvement underlying the pathogenesis of COVID-19 cardiovascular complications.","authors":"Antoine Fakhry AbdelMassih, David Ramzy, Lauren Nathan, Silvia Aziz, Mirette Ashraf, Nourhan Hatem Youssef, Nouran Hafez, Rana Saeed, Hala Agha","doi":"10.1097/XCE.0000000000000207","DOIUrl":"10.1097/XCE.0000000000000207","url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19) has been declared a pandemic on 11 March 2020 by the WHO. Despite being mainly a respiratory virus, cardiac complications have been described. These range from sudden cardiac death to subtle diastolic dysfunction after recovery from COVID-19. The commonest cardiac presentation to date is acute heart failure resulting from biventricular or left ventricular hypokinesis and elevation of cardiac troponins. It has been shown that COVID-19 downregulates angiotensin-converting enzyme-2, which has protective effects on the endothelium and cardiomyocytes. It has also been proven that COVID-19 induces a state of hypercytokinaemia, some cytokines such as interleukin-1 and interleukin-6 have an injurious effect on the myocardium and endothelium, respectively. Such pathogenic mechanisms might play a crucial role in induction of cardiomyocyte injury and impaired myocardial perfusion probably through coronary endothelial dysfunction. The understanding and linking of such mechanisms might help in tailoring drug repurposing for treatment or prophylaxis of COVID-19 cardiovascular complications.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 3","pages":"121-124"},"PeriodicalIF":2.3,"publicationDate":"2020-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410028/pdf/xce-9-121.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38271998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jamie S Y Ho, Bryan Mui, Ching-Hui Sia, Andie H Djohan, Shao-Feng Mok, Mark Y Chan, Anand A Ambhore
{"title":"A 78-year-old male with inferior ST-segment elevation on electrocardiogram, diabetic ketoacidosis and acute pancreatitis.","authors":"Jamie S Y Ho, Bryan Mui, Ching-Hui Sia, Andie H Djohan, Shao-Feng Mok, Mark Y Chan, Anand A Ambhore","doi":"10.1097/XCE.0000000000000205","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000205","url":null,"abstract":"<p><p>A 78-year-old male presented with shortness of breath, metabolic acidosis, severe hyperglycaemia and ketonemia. Inferior ST-elevation was present on 12-lead ECG with raised troponin I, but coronary arteries were normal on emergency cardiac catheterization. Despite no previous history of diabetes mellitus and normal HbA1c levels 7 months prior, diabetic ketoacidosis (DKA) was diagnosed, complicated by subsequent shock. The underlying cause was acute pancreatic disease, supported by elevated pancreatic enzyme levels and a history of chronic heavy alcohol use. There are no previous reports, to our knowledge, of patients with acute pancreatitis presenting to the ED with secondary DKA mimicking STEMI.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 4","pages":"186-188"},"PeriodicalIF":2.3,"publicationDate":"2020-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673775/pdf/xce-9-186.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38641609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prevention and management of cardiovascular disease in patients with diabetes: current challenges and opportunities.","authors":"Dennis Bruemmer, Steven E Nissen","doi":"10.1097/XCE.0000000000000199","DOIUrl":"10.1097/XCE.0000000000000199","url":null,"abstract":"<p><p>More than 100 million people in the USA have diabetes or prediabetes and are at high risk for developing cardiovascular disease. Current evidence-based guidelines support a multifactorial approach in patients with diabetes, including lifestyle intervention and pharmacological treatment of hyperglycemia, hypertension, and dyslipidemia. In addition, recent cardiovascular outcome trials demonstrated that sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists improve cardiovascular outcomes in patients with diabetes. Albeit this evidence, over 80% of patients with diabetes do not achieve the recommended treatment goals. Considering the rising burden of cardiovascular complications, there is need to improve the quality of care in patients with diabetes. In this review, we discuss the current quality of health care in patients with diabetes in the USA, identify barriers to achieve guideline-recommended treatment goals and outline opportunities for the improvement in caring for patients with diabetes.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 3","pages":"81-89"},"PeriodicalIF":1.3,"publicationDate":"2020-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410032/pdf/xce-9-081.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38271991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists.","authors":"Gerardo Rodriguez-Araujo","doi":"10.1097/XCE.0000000000000197","DOIUrl":"10.1097/XCE.0000000000000197","url":null,"abstract":"<p><p>Type 2 diabetes mellitus is not just a risk factor but a progression factor for a plethora of multi-organ complications, including the liver and the vascular system. The profibrogenic-inflammatory liver disease nonalcoholic steatohepatitis affects patient's mortality and overall cardiovascular and liver-related complications. There is an evident overlap between these diseases; therefore, there are important implications for endocrinologists, cardiologists, and hepatologists when treating these patients. In addition, as newly approved nonalcoholic steatohepatitis pharmacotherapy is expected to be available early this year, clinicians need to be able to identify patients with type 2 diabetes mellitus that are at risk of advanced liver fibrosis to establish adequate and efficient management plans to limit or avoid cardiovascular or liver-related complications. In this review, we summarize the current knowledge in the nonalcoholic steatohepatitis field with potential value for clinicians focusing on the implications of the overlap between type 2 diabetes mellitus, cardiovascular disease, and nonalcoholic steatohepatitis, the available diagnostic tools for risk stratification, management pathways, and nonalcoholic steatohepatitis pharmacotherapy, including antidiabetic and cardiovascular drugs that may be beneficial or detrimental to their patients.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 3","pages":"96-100"},"PeriodicalIF":2.3,"publicationDate":"2020-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410017/pdf/xce-9-096.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38271993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}